Xtandi

failure crash no fail rocket cancelled end

Essa drops lead cancer drug after falling short against Xtandi

Essa's sole clinical-stage candidate was on track to fall short in a phase 2 prostate cancer study, leading the biotech to “review strategic options.”

James Waldron Nov 1, 2024 7:33am

Arvinas eyes a busy 2021 as protein degraders gather steam

Dec 14, 2020 10:32am

Astellas to halt work at R&D subsidiary amid restructuring plan

May 23, 2018 2:16pm

Micrograph showing the most common prostate cancer

Researchers create test to predict response to Xtandi, Zytiga

May 5, 2017 9:24am

Tokai up on potential sale, reverse merger after PhIII failure

Sep 8, 2016 8:29am

PhIII failure, 60% of staffers axed; now Tokai has some more bad news

Aug 23, 2016 6:26am